Abstract
Background: Syndecan-1 binds to various extracellular matrix components via its heparan sulfate glycosaminoglycans. The aim of this study was to investigate syndecan-1 expression in endometrial cancers. Patients and methods: We investigated the expression of the syndecan-1 core protein by immunohistochemistry in 109 endometrial cancers, and analyzed correlation with various clinicopathological features, including patient outcome. Results: Epithelial syndecan-1 expression was significantly lower in advanced stage, high grade, deep myometrial invasion, cervical involvement, lymph node metastasis, lymph vascular space involvement and positive peritoneal cytology. Stromal syndecan-1 expression was significantly higher in high-grade tumors. The disease-free and overall survival rates of patients exhibiting both low epithelial and high stromal syndecan-1 expression was poor. Multivariate analysis showed that high stromal syndecan-1 expression was an independent prognostic factor for both disease-free and overall survival. Low epithelial syndecan-1 expression was a prognostic factor only in the univariate analysis. Conclusions: Loss of epithelial syndecan-1 and induction of stromal syndecan-1 expression may be associated with tumor progression. Stromal syndecan-1 expression can serve as an indicator of poor prognosis in patients with endometrial cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 1109-1115 |
| Number of pages | 7 |
| Journal | Annals of Oncology |
| Volume | 16 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - Jul 2005 |
Fingerprint
Keywords
- Endometrial cancer
- Prognosis
- Syndecan-1
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Prognostic significance of syndecan-1 expression in human endometrial cancer. / Hasengaowa; Kodama, J.; Kusumoto, T.; Shinyo, Y.; Seki, N.; Hiramatsu, Y.
In: Annals of Oncology, Vol. 16, No. 7, 07.2005, p. 1109-1115.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Prognostic significance of syndecan-1 expression in human endometrial cancer
AU - Hasengaowa,
AU - Kodama, J.
AU - Kusumoto, T.
AU - Shinyo, Y.
AU - Seki, N.
AU - Hiramatsu, Y.
PY - 2005/7
Y1 - 2005/7
N2 - Background: Syndecan-1 binds to various extracellular matrix components via its heparan sulfate glycosaminoglycans. The aim of this study was to investigate syndecan-1 expression in endometrial cancers. Patients and methods: We investigated the expression of the syndecan-1 core protein by immunohistochemistry in 109 endometrial cancers, and analyzed correlation with various clinicopathological features, including patient outcome. Results: Epithelial syndecan-1 expression was significantly lower in advanced stage, high grade, deep myometrial invasion, cervical involvement, lymph node metastasis, lymph vascular space involvement and positive peritoneal cytology. Stromal syndecan-1 expression was significantly higher in high-grade tumors. The disease-free and overall survival rates of patients exhibiting both low epithelial and high stromal syndecan-1 expression was poor. Multivariate analysis showed that high stromal syndecan-1 expression was an independent prognostic factor for both disease-free and overall survival. Low epithelial syndecan-1 expression was a prognostic factor only in the univariate analysis. Conclusions: Loss of epithelial syndecan-1 and induction of stromal syndecan-1 expression may be associated with tumor progression. Stromal syndecan-1 expression can serve as an indicator of poor prognosis in patients with endometrial cancer.
AB - Background: Syndecan-1 binds to various extracellular matrix components via its heparan sulfate glycosaminoglycans. The aim of this study was to investigate syndecan-1 expression in endometrial cancers. Patients and methods: We investigated the expression of the syndecan-1 core protein by immunohistochemistry in 109 endometrial cancers, and analyzed correlation with various clinicopathological features, including patient outcome. Results: Epithelial syndecan-1 expression was significantly lower in advanced stage, high grade, deep myometrial invasion, cervical involvement, lymph node metastasis, lymph vascular space involvement and positive peritoneal cytology. Stromal syndecan-1 expression was significantly higher in high-grade tumors. The disease-free and overall survival rates of patients exhibiting both low epithelial and high stromal syndecan-1 expression was poor. Multivariate analysis showed that high stromal syndecan-1 expression was an independent prognostic factor for both disease-free and overall survival. Low epithelial syndecan-1 expression was a prognostic factor only in the univariate analysis. Conclusions: Loss of epithelial syndecan-1 and induction of stromal syndecan-1 expression may be associated with tumor progression. Stromal syndecan-1 expression can serve as an indicator of poor prognosis in patients with endometrial cancer.
KW - Endometrial cancer
KW - Prognosis
KW - Syndecan-1
UR - http://www.scopus.com/inward/record.url?scp=25444495294&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=25444495294&partnerID=8YFLogxK
U2 - 10.1093/annonc/mdi224
DO - 10.1093/annonc/mdi224
M3 - Article
C2 - 15851381
AN - SCOPUS:25444495294
VL - 16
SP - 1109
EP - 1115
JO - Annals of Oncology
JF - Annals of Oncology
SN - 0923-7534
IS - 7
ER -